Our findings suggest that the appropriate target for assessment of TS expression as prognostic/predictive marker is a subgroup of colon cancers with an immunophenotype other than p21WAF1+/p53-, and that only in this subgroup high TS expression is associated with an unfavorable DFS and OS. Here, TP53 is linked to malignant colon neoplasm.